Differences in cancer drug assessment between Spain and the United Kingdom
| Autor: | Ana Lozano-Blázquez, Miguel-Ángel Calleja-Hernández, Rumona Dickson, María-Dolores Fraga-Fuentes, Fernando Martínez-Martínez |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Cancer Research
medicine.medical_specialty Technology Assessment Biomedical Time Factors Drug reimbursement media_common.quotation_subject Cost-Benefit Analysis Cancer drugs Biomedical Technology Nice Antineoplastic Agents Drug Costs Decision Support Techniques Workflow Excellence Neoplasms Agency (sociology) Medicine Humans Drug Approval health care economics and organizations Decision Making Organizational computer.programming_language media_common Government Health Care Rationing business.industry United Kingdom Treatment Outcome Oncology Spain Family medicine Insurance Health Reimbursement Health Resources business computer Needs Assessment Appraisal process |
| Zdroj: | European journal of cancer (Oxford, England : 1990). 51(13) |
| ISSN: | 1879-0852 |
| Popis: | Objectives There is no Spanish Government agency resembling the National Institute for Health and Care Excellence (NICE) in the United Kingdom (UK) that carries out a centralised evaluation and makes decisions about funding. Therefore, we aim to assess the differences between NICE and the Spanish bodies in terms of their respective processes. We compare the decisions concerning cancer drugs in the assessments made by NICE/Single Technology Appraisal with assessments made by MADRE methodology. Methods We included all cancer drugs assessed by NICE and all MADRE reports made using a shared reports process (GENESIS) and reports from Catalonia (CAMDHA) and Andalucia (GFTHA). We compared the number of drugs assessed, the decisions taken by NICE and Spanish organizations and timelines. Results Between January 2011 and December 2013 NICE appraised 24 cancer drugs. In Spain, 44 reports were produced using MADRE methodology. For the 14 drugs assessed by both NICE and Spanish bodies, NICE rejected a high proportion of the drugs (50% versus 26%). GENESIS, with a median of 8 months, made decisions more quickly than NICE (13.5 months) and GFTHA (17 months). The slowest organisation was CAMDHA (24.5 months). Conclusions More drugs are assessed in Spain than by NICE because there are more organisations in Spain doing this work and their processes are simpler. NICE rejects more drugs as it uses cost-effectiveness thresholds that lead to a ‘not-recommended’ decision, and Spanish bodies recommend cancer drugs for subgroups of patients where better results can be obtained. Timelines are better for Spanish Committees, probably because of the greater number of steps in the appraisal process by NICE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect